The Multicenter Study of Hydroxyurea (MSH) is a phase III clinical trial that attempts to determine whether hydroxyurea can reduce sickle cell pain crisis attacks by at least 50 percent. The study has a double-blind, placebo-controlled design. All 299 patients, enrolled nationwide, are adults with sickle cell anemia (Hb SS); Howard University has contributed patients to the study. The clinical trial involves the daily administration of hydroxyurea (15-30mg/kg day) or placebo capsules, which are dispensed during outpatient visits every two weeks. Data on vaso- occlusive crises will be collected by the clinical centers and verified by a """"""""blinded"""""""" central committee that will define whether each medical contact was, or was not, a vaso-occlusive event according to standardized criteria. Enrollment for this trial started in early 1992, and data collection to test the main hypothesis is scheduled to close by the end of April 1995. At that time, each patient will have been on the maximum tolerated hydroxyurea dose for at least one year. The study, however, will continue for another six months (until September 1, 1995) for purposes of data editing and clean-up, and for analysis of secondary endpoints. In addition, it is quite possible that the participating clinical centers will be funded for follow-up of study participants in an attempt to determine if there are long-term adverse effects of hydroxyurea administration. If this clinical trial shows that hydroxyurea ameliorates the vaso-occlusive severity of sickle cell anemia (Hb SS), there are plans for testing it in other patients, such as those with sickle-cell hemoglobin-C disease (Hb SC), who are not eligible for the current protocol.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
1M01RR010284-01A1
Application #
5225837
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1996
Total Cost
Indirect Cost
Christensen, Kurt D; Uhlmann, Wendy R; Roberts, J Scott et al. (2018) A randomized controlled trial of disclosing genetic risk information for Alzheimer disease via telephone. Genet Med 20:132-141
Doumatey, Ayo P; He, William J; Gaye, Amadou et al. (2018) Circulating MiR-374a-5p is a potential modulator of the inflammatory process in obesity. Sci Rep 8:7680
Guan, Yue; Roter, Debra L; Wolff, Jennifer L et al. (2018) The impact of genetic counselors' use of facilitative strategies on cognitive and emotional processing of genetic risk disclosure for Alzheimer's disease. Patient Educ Couns 101:817-823
Mullins, Tanya L Kowalczyk; Li, Su X; Bethel, James et al. (2018) Sexually transmitted infections and immune activation among HIV-infected but virally suppressed youth on antiretroviral therapy. J Clin Virol 102:7-11
Faruque, Mezbah U; Chen, Guanjie; Doumatey, Ayo P et al. (2017) Transferability of genome-wide associated loci for asthma in African Americans. J Asthma 54:1-8
Guan, Yue; Roter, Debra L; Erby, Lori H et al. (2017) Disclosing genetic risk of Alzheimer's disease to cognitively impaired patients and visit companions: Findings from the REVEAL Study. Patient Educ Couns 100:927-935
Nandakumar, Priyanka; Lee, Dongwon; Richard, Melissa A et al. (2017) Rare coding variants associated with blood pressure variation in 15?914 individuals of African ancestry. J Hypertens 35:1381-1389
Lieberman, Richard; Armeli, Stephen; Scott, Denise M et al. (2016) FKBP5 genotype interacts with early life trauma to predict heavy drinking in college students. Am J Med Genet B Neuropsychiatr Genet 171:879-87
Christensen, Kurt D; Roberts, J Scott; Whitehouse, Peter J et al. (2016) Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease: A Randomized Trial. Ann Intern Med 164:155-63
Armeli, Stephen; O'Hara, Ross E; Covault, Jon et al. (2016) Episode-specific drinking-to-cope motivation and next-day stress-reactivity. Anxiety Stress Coping 29:673-84

Showing the most recent 10 out of 205 publications